Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have one of these lymphoma types: diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia/small lymphocytic leukemia that has returned or not responded to prior therapy.
- You identify as Black or African American, Hispanic or Latino, American Indian/Native Alaskan, Pacific Islander/Native Hawaiian, or another group that is not non-Hispanic White or non-Hispanic Asian.
- You have at least one measurable tumor or abnormal lymphocyte count.
- Your kidneys, liver, and blood counts meet minimum levels, and you are not pregnant or breastfeeding.
- You have not taken a BCL2 inhibitor (like venetoclax) for 2 months or more, or your disease did not get worse on it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two targeted oral medications, zanubrutinib and sonrotoclax, for people with CLL or SLL that has come back. The goal is to see if combining them can control the disease better and with fewer side effects than current options.
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
This trial tests two oral medications (sonrotoclax and zanubrutinib) for people newly diagnosed with CLL or SLL who need treatment. The goal is to see if this combination is effective and safe.
Hear when a new Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.